NCT02312622 2023-12-12
Phase 2 Etirinotecan Pegol in Refractory Brain Metastases & Advanced Lung Cancer / Metastatic Breast Cancer
Stanford University
Phase 2 Completed
Clinical Trials
4 trialsNCT01773109 2020-04-03
Etirinotecan Pegol (NKTR-102) in NSCLC
Abramson Cancer Center at Penn Medicine
Phase 2 Completed
NCT01876446 2020-03-17
Pegylated Irinotecan NKTR 102 in Treating Patients With Relapsed Small Cell Lung Cancer
Roswell Park Cancer Institute
Phase 2 Completed
NCT01663012 2016-02-24
Phase II NKTR-102 In Bevacizumab-Resistant High Grade Glioma
Stanford University
Phase 2 Completed